44 results about "Cannabinoid receptor" patented technology

Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The present application relates to a kind of annelated derivative and its preparation method and use, specifically provide the compound or its pharmaceutically acceptable salt, stereoisomer as selective agonist of cannabinoid receptor CB2, wherein the compound has the structure of formula (I).

The present invention relates to novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2. Specifically, the invention relates to compounds of formula (I) wherein A, A2, X and R1-R3 are as defined in the description and in the claims. The compounds of formula (I) can be used as medicaments due to their inhibition of cannabinoid receptor 2. # imgabs0 #

Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and / or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

This document relates to purine compounds, pharmaceutical compositions comprising the purine compounds and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the purine compounds or tautomeric forms and / or salts thereof have the formula (I): wherein R1 to R4 are as defined herein. # imgabs0 #

Disclosed are therapeutic combinations for eliciting an enhanced human intimacy mental state, such as by using a composition comprising an imidazoline receptor agent, a cannabinoid receptor agent and / or a serotonin receptor agent. Also disclosed are certain selective receptor agents, pharmaceutical compositions thereof, and methods for their use in treating mental health conditions, improving mental health and mental function, and designing and generating mental states or mental states enhancing human intimacy.

The present invention provides covalent fluorescent probes for cannabinoid receptor 2 (“CB2”) having the general formula (I)wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Therapeutic combinations for inducing entactogenic states of mind, such as through the use of compositions comprising imidazoline receptor agents, cannabinoid receptor agents, and / or serotonin receptor agents, are disclosed. Also disclosed are certain selective receptor agents, pharmaceutical compositions thereof, and methods of their use for treating mental health conditions, improving mental health and mental function, and designing and creating entactogenic states of mind or mood.

Disclosed herein is an engineered eukaryotic cell which expresses a heterologous G protein coupled receptor (GPCR), wherein native Ste2 and / or Ste3 have been replaced with a heterologous GPCR; and further wherein native G alpha protein (Gpa1) has been replaced with a gene encoding a chimeric Gpa1. The GPCR disclosed herein can be a cannabinoid receptor, such as human cannabinoid receptor type I (CB1R). Also disclosed are methods of making the engineered eukaryotic cell, and methods of using the engineered eukaryotic cell. Also encompassed by this invention are biosensors comprising CB1R and CB2R, and methods of using them.

The present invention provides reversible fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I), wherein A, R2 and R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potency and pharmacokinetic properties. Methods of treating diseases mediated by CB1R, such as substance abuse and obesity, using the analogs are described.

Heteroaromatic compounds are provided which are allosteric modulators of the cannabinoid receptors and which are useful for the treatment of glaucoma, pain, neuropathic pain, post-traumatic stress disorder (PTSD), and neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases where cannabinoid receptors are involved.

The present application provides a radiolabeled compound targeting cannabinoid receptor type 1 with radionuclide 18F. The present application also provides a method for preparing the compound and its use as a positron emission tomography (PET) imaging agent.

The present invention is directed to a dual agonist of cannabinoid receptor 2 and of opioid receptor, composition comprising same, and methods of using same in the treatment of pain, in a subject in need thereof.

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None

The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH).

The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

Disclosed herein is an engineered eukaryotic cell which expresses a heterologous G protein coupled receptor (GPCR), wherein native Ste2 and / or Ste3 have been replaced with a heterologous GPCR: and further wherein native G alpha protein (Gpa1) has been replaced with a gene encoding a chimeric Gpa1. The GPCR disclosed herein can be a cannabinoid receptor. such as human cannabinoid receptor type I (CB1R). Also disclosed are methods of making the engineered eukaryotic cell. and methods of using the engineered eukaryotic cell. Also encompassed by this invention are biosensors comprising CB1R and CB2R. and methods of using them.

Disclosed are therapeutic combinations for eliciting an entactogenic mindstate, such as through use of compositions comprising imidazoline receptor agents, cannabinoid receptor agents, and / or serotonin receptor agents. Also disclosed are certain selective receptor agents, pharmaceutical compositions thereof, and methods for their use to treat mental health conditions, improve mental health and mental functioning, and design and create entactogenic mental states or mindstates.

This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.

The present invention relates to biologically active compounds of formula (I) capable of interacting with the CB1 and / or the CB2 cannabinoid receptors. The present invention also relates to the use of said compounds in the treatment and / or prevention of CB1 and / or CB2 cannabinoid receptors related diseases.

The present invention provides: a covalent fluorescent probe for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p and R1 to R4 are as described herein; comprising the compound; processes for preparing the compounds; and methods of using the compounds. # imgabs0 #

Compounds having useful cannabinoid receptor modulating properties. The compounds may be useful in treating complications arising from metabolic, inflammatory and fibrotic disorders.

Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.

An antibody specifically binding to CB1 or an antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof and a host cell comprising the same, and therapeutic and diagnostic uses of these antibodies or antigen-binding fragments thereof.

Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and obesity, are described.

A method for accessing CB1 and CB2 receptor-active compounds via a homogeneous catalytic reduction of unsaturated precursors is described. The method is safe, effective, and stereoselective. In particular, the method employing optimized cooperative hydrogen-atom transfer (HAT) reaction conditions affords HHCs from THCs in excellent yield and with superior stereoselectivity for the more bioactive isomer (9R)-HHC.